Jim Cramer Cautions Investors on Nuvation Bio as Wall Street Targets 113% Upside

Television commentator Jim Cramer provided a sharp assessment of biopharmaceutical firm Nuvation Bio Inc. during a September 3, 2026 episode of CNBC's "Mad Money." Responding to a viewer asking about the surging oncology stock, Cramer described the equity in five words: "This is a pure spec." His remarks were first reported by Yahoo Finance.

The phrase, short for pure speculation, denotes a company whose equity value relies on future clinical prospects rather than immediate cash flow or net profits. Although Cramer did not criticize the underlying research pipeline at Nuvation Bio, he cautioned that the stock lacks strong financial support, leaving investors exposed to sudden price drops if clinical trial results fail to meet expectations.

Nuvation Bio operates as an early commercial-stage oncology developer. While the firm maintains an approved therapeutic on the market, the majority of its valuation hinges on experimental drug candidates advancing through clinical evaluations. According to financial data from StockAnalysis, Wall Street projects that Nuvation Bio will record a full-year net loss for the period ending December 2026, requiring the business to rely heavily on cash reserves to fund ongoing research.

The caution from Cramer comes despite notable development milestones by the biopharmaceutical firm. In August 2026, the U.S. Food and Drug Administration granted Fast Track Designation to Safusidenib, Nuvation's investigational treatment for IDH1-mutant glioma, an aggressive form of brain tumor with limited therapeutic options. Safusidenib is currently undergoing pivotal late-stage clinical testing aimed at accelerating potential regulatory approvals.

Alongside its investigational pipeline, Nuvation Bio has gained initial market traction with its approved lung cancer medication, IBTROZI. During the first five months of 2026, IBTROZI emerged as the most prescribed treatment in its specific class for newly diagnosed patients. This early commercial momentum has driven positive sentiment among sell-side equity analysts.

Wall Street price targets remain significantly higher than Cramer's cautious outlook. Institutional analysts maintain an average 12-month price target of $14.50 per share for Nuvation Bio, representing an estimated 113% upside from its recent trading price around $6.80. Several research firms raised their target prices following the launch performance of IBTROZI and the FDA designation for Safusidenib.

The gap between sell-side projections and Cramer's warning reflects differing investment timelines and risk tolerances. Equity analysts are evaluating prospective revenue over a 12-month horizon, whereas Cramer emphasized the inherent volatility typical of clinical-stage biotechs, where unexpected trial setbacks can severely erode market capitalizations.

To manage risks associated with speculative biopharmaceutical equities, Cramer suggested several portfolio management guidelines. He advised investors to restrict speculative positions to small satellite holdings while keeping primary capital in diversified, low-risk assets. Additionally, he recommended monitoring quarterly cash runway figures for potential share dilution and considering partial profit-taking during rallies driven by positive regulatory updates.